

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>F2 MG Ltd</u> <hr/> (Last) (First) (Middle) C/O LJ FIDUCIARY, 8, RUE SAINT-LEGER <hr/> (Street) GENEVA V8 CH-1205 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/28/2022	3. Issuer Name and Ticker or Trading Symbol <u>Allovir, Inc.</u> [ ALVR ]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,059,884	D <sup>(1)</sup>	
Common Stock	668,072	I <sup>(2)</sup>	By F2-TPO Investments, LLC
Common Stock	2,038,583	I <sup>(3)</sup>	By F2 MC, LLC
Common Stock	4,193,874	I <sup>(4)</sup>	By F2 Capital I 2020 LLC
Common Stock	867,678	I <sup>(5)</sup>	By F2 Bioscience AV 2022 LLC

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

1. Name and Address of Reporting Person* <u>F2 MG Ltd</u> <hr/> (Last) (First) (Middle) C/O LJ FIDUCIARY, 8, RUE SAINT-LEGER <hr/> (Street) GENEVA V8 CH-1205 <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>Globeways Holdings Ltd</u> <hr/> (Last) (First) (Middle) C/O LJ FIDUCIARY, 8, RUE SAINT-LEGER <hr/> (Street) GENEVA V8 CH-1205 <hr/> (City) (State) (Zip)		
---	--	--

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">F2 - TPO Investments LLC</a>		
(Last)	(First)	(Middle)
C/O SINGER MCKEON, 8 WEST 38TH STREET, SUITE 1001		
(Street)		
NEW YORK	NY	10018
(City)	(State)	(Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">F2 MC, LLC</a>		
(Last)	(First)	(Middle)
C/O SINGER MCKEON, 8 WEST 38TH STREET, SUITE 1001		
(Street)		
NEW YORK	NY	10018
(City)	(State)	(Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">F2 Capital I 2020</a>		
(Last)	(First)	(Middle)
C/O SINGER MCKEON, 8 WEST 38TH STREET, SUITE 1001		
(Street)		
NEW YORK	NY	10018
(City)	(State)	(Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">F2 Bioscience AV 2022 LLC</a>		
(Last)	(First)	(Middle)
C/O SINGER MCKEON, 8 WEST 38TH STREET, SUITE 1001		
(Street)		
NEW YORK	NY	10018
(City)	(State)	(Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Globeways Holdings II Ltd</a>		
(Last)	(First)	(Middle)
C/O SINGER MCKEON, 8 WEST 38TH STREET, SUITE 1001		
(Street)		
NEW YORK	NY	10018
(City)	(State)	(Zip)

Explanation of Responses:

